Test accurately IDs people whose gonorrhea can be cured with simple oral antibiotic
A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that causes the infection was becoming resistant to it.In research published in the peer-reviewed journal Clinical Infectious Diseases,a UCLA-led team found thatof106 subjectsthe test identified as having a strain ofgonorrhea called wild-type gyrA serine, all were cured with a single dose of oral ciprofloxacin. Though the test has been available for three years, this is the first time it has been systematically studied in humans.The new test gives doctors more choices to treat thesexually transmittedinfection and could help slow down the spread of drug-resistant gonorrhea, said Dr. Jeffrey Klausner, the study ’s lead author and a professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA.“Gonorrhea is one of the most common drug-resistant infections worldwide and is becoming harder to treat. Current treatment methods require an antibiotic injection, which is expensive and painful,” said Klausner, who is also an adjunct professor of epidemiology at the UCLA Fielding School of Public Health. “This new test could make it easier and safer to treat gonorrhea with different antibiotics, including one pill given by mouth. “Using a pill instead of a shot would also make it...
Conditions: Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary Interventions: Drug: Linezolid 600 mg; Drug: Linezolid 1200 mg (QD); Drug: Linezolid 1200 mg (TIW); Drug: Bedaquiline 200 mg; Drug: Bedaquiline 100 mg; Drug: Delamanid 300 mg; Drug: Clofazimine 300 mg; Drug: Clofazimine 100 mg Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
(NIH/National Institute of Allergy and Infectious Diseases) Using viruses instead of antibiotics to tame troublesome drug-resistant bacteria is a promising strategy, known as bacteriophage or " phage therapy. " Scientists at the National Institutes of Health have used two different bacteriophage viruses individually and then together to successfully treat research mice infected with multidrug-resistant Klebsiella pneumoniae sequence type 258 (ST258).
CONCLUSION: We found relatively low adherence to international guidelines in our center that could be related to restricted definitions of optimal antibiotic therapy. Despite most patients received logical antimicrobial therapy, actions should be taken into account to reach optimal antibiotic usage.PMID:33602106 | DOI:10.2174/1574886316666210218104644
More News: Allergy | Allergy & Immunology | Ceftriaxone | Centers for Disease Control and Prevention (CDC) | Cipro | Ciprofloxacin | Epidemiology | Genetics | Infectious Diseases | International Medicine & Public Health | Men | Multidrug Resistance | National Institutes of Health (NIH) | Rocephin | Study | Universities & Medical Training | University of Washington | USA Health